The Pharmacologic Treatment of Schizophrenia-2021.

[1]  J. Krystal,et al.  A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia. , 2020, The New England journal of medicine.

[2]  R. Kotov,et al.  Lead-Time Bias Confounds Association Between Duration of Untreated Psychosis and Illness Course in Schizophrenia. , 2020, The American journal of psychiatry.

[3]  Andrea Cipriani,et al.  Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis , 2019, The Lancet.

[4]  A. Malhotra,et al.  Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis. , 2019, The American journal of psychiatry.

[5]  J. Addington,et al.  Interventions and social functioning in youth at risk of psychosis: A systematic review and meta‐analysis , 2018, Early intervention in psychiatry.

[6]  M. Ruggeri,et al.  Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression , 2018, JAMA psychiatry.

[7]  P. McGorry,et al.  Beyond the “at risk mental state” concept: transitioning to transdiagnostic psychiatry , 2018, World psychiatry : official journal of the World Psychiatric Association.

[8]  J. Lieberman,et al.  The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. , 2017, The American journal of psychiatry.

[9]  D. Wiersma,et al.  Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. , 2013, JAMA psychiatry.

[10]  S. Leucht,et al.  How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials , 2009, Molecular Psychiatry.